Kathryn Miller

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.

Jennifer G. Robinson, J. Robinson, H. Bays, 2016, The American journal of cardiology.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials.

D. Gaudet, P. Minini, B. Cariou, 2016, International journal of cardiology.

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Jennifer G. Robinson, J. Robinson, W. Sasiela, 2017, Journal of the American College of Cardiology.

Efficacy of alirocumab in heterozygous familial hypercholesterolemia or high cv risk populations: pooled analyses of eight phase 3 trials

D. Gaudet, P. Minini, B. Cariou, 2015 .

Efficacy of alirocumab according to background statin intensity and other lipid-lowering therapy in heterozygous familial hypercholesterolemia or high cv risk populations: phase 3 sub-group analyses

M. Krempf, P. Minini, J. Bergeron, 2015 .

POOLED SAFETY AND ADVERSE EVENTS IN NINE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 AND 3 CLINICAL TRIALS OF ALIROCUMAB

Jennifer G. Robinson, H. Bays, U. Chaudhari, 2015 .

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab.

C. Cannon, E. Bruckert, D. Kereiakes, 2019, Journal of clinical lipidology.

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Jennifer G. Robinson, W. Sasiela, R. Rosenson, 2017, Journal of the American College of Cardiology.